← Eisai Co. overview

Eisai Co. vs Opko Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Eisai Co., Ltd. (4523.JP)

Q3 2026
▲4

Eisai Q3: Leqembi at-home approvals and oncology wins drive growth

  • Leqembi at-home subcutaneous approval and launches The FDA approved at-home subcutaneous Leqembi/Iqlik, with launches in the US, plus approvals in China and Japan enabling at-home use. This expands patient access and convenience, potentially boosting sales.

    This is a major new approval and launch that directly impacts Eisai's growth prospects.

  • Strong Leqembi sales and royalty growth Q2 Leqembi sales reached ¥29.3bn, with royalties up 43% excluding China stockpiling. This indicates robust demand and successful commercialization.

    Sales and royalty figures are key financial metrics showing Leqembi's market performance.

  • Oncology pipeline advances UK validated taletrectinib, and the FDA approved WELIREG plus LENVIMA for advanced kidney cancer. These expand Eisai's oncology portfolio and revenue potential.

    New approvals and validations in oncology represent additional growth drivers beyond Leqembi.

  • AI drug-discovery partnership with Nvidia Eisai joined Nvidia’s AI drug-discovery push, which could enhance future pipeline productivity and innovation.

    This strategic move may improve long-term R&D efficiency and is a new development.

August 2026
▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

  • Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.

    Shows strong sales momentum, a key driver of Eisai's earnings and stock price.

  • FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.

    New approval expands market access and convenience, directly driving future sales.

  • Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.

    Reimbursement is crucial for uptake; this opens a new market for Eisai.

  • China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.

    Subcutaneous approval in key markets improves convenience and access, driving demand.

  • FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.

    New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

Latest
▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

  • Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.

    Shows strong sales momentum, a key driver of Eisai's earnings and stock price.

  • FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.

    New approval expands market access and convenience, directly driving future sales.

  • Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.

    Reimbursement is crucial for uptake; this opens a new market for Eisai.

  • China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.

    Subcutaneous approval in key markets improves convenience and access, driving demand.

  • FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.

    New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

July 2026
▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

  • FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.

    This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.

  • Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.

    New real-world data strengthens the commercial case for Leqembi beyond clinical trials.

  • UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.

    New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.

  • Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.

    New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

  • FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.

    This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.

  • Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.

    New real-world data strengthens the commercial case for Leqembi beyond clinical trials.

  • UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.

    New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.

  • Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.

    New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

Opko Health Inc (OPK)

© 2026 MarketIVWhy